News Releases

Date Title and Summary View
Jan 11, 2019
Johnson & Johnson Recommends Rejection Of Below-Market "Mini-Tender" Offer By Peer & Peri LLC
NEW BRUNSWICK, N.J. , Jan. 11, 2019 /PRNewswire/ --  Johnson & Johnson (NYSE: JNJ) received notice of an unsolicited "mini-tender" offer by Peer & Peri LLC (Peer & Peri) to purchase up to 30,000 shares of common stock of Johnson & Johnson , representing approximately 0.001% of the company's
Jan 11, 2019
Johnson & Johnson Announces completion of Offer for Ci:z Holdings Co., Ltd.
NEW BRUNSWICK, N.J. , Jan. 11, 2019 /PRNewswire/ --  Johnson & Johnson (NYSE: JNJ) today announced that the conditions to its public tender offer for all of the outstanding shares of Ci:z Holdings Co., Ltd. (TYO: 4924) (the "Company") not already held by Johnson & Johnson or its affiliates that was
Jan 07, 2019
Jan 02, 2019
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2019
NEW BRUNSWICK, N.J. , Jan. 2, 2019 /PRNewswire/ --  Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2019 of $0.90 per share on the company's common stock. The dividend is payable on March 12, 2019 to shareholders of
Dec 24, 2018
Johnson & Johnson to Participate in 37th Annual JP Morgan Health Care Conference
NEW BRUNSWICK, N.J. , Dec. 24, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 37 th Annual JP Morgan Health Care Conference on Monday, Jan. 7 th , at the Westin St. Francis in San Francisco.  Joseph J. Wolk , Executive Vice President and Chief Financial Officer; Jennifer
Dec 20, 2018
Dec 19, 2018
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
NEW BRUNSWICK, N.J. , Dec. 19, 2018 /PRNewswire/ --  Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, January 22 nd , to review fourth-quarter results.  Alex Gorsky , Chairman and Chief Executive Officer; Joseph J.
Dec 17, 2018
Johnson & Johnson Announces $5 Billion Share Repurchase Program
NEW BRUNSWICK, N.J. , Dec. 17, 2018 /PRNewswire/ --  Johnson & Johnson (NYSE: JNJ) today announced that the Board of Directors has authorized the repurchase of up to $5 billion of the company's common stock. "Based on our continued strong performance and, more importantly, the confidence we have in
Dec 14, 2018
Janssen Submits Supplemental New Drug Application (sNDA) to FDA for XARELTO® (rivaroxaban) to Prevent Venous Thromboembolism (VTE) in Acute Medically Ill Patients
  If approved, this will add to the five existing VTE indications for XARELTO® –  the most studied anticoagulant available to the most groups of patients     Despite being largely preventable, VTE remains a significant risk for the eight million Americans with acute medical illnesses    TITUSVILLE,
Dec 14, 2018
Statement on Reuters Talc Article
NEW BRUNSWICK, N.J. , Dec. 14, 2018 /PRNewswire/ --  Johnson & Johnson (NYSE: JNJ) today issued the following statement regarding speculation about the safety of our products. The Reuters article is one-sided, false, and inflammatory. Johnson & Johnson's baby powder is safe and asbestos-free.
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.